A clinical trial for people living with phenylketonuria (PKU)
A clinical trial for people living with PKU
The purpose of the Synpheny-3 clinical trial is to evaluate an investigational drug, SYNB1934. Its goal: to see how well and how safely SYNB1934 reduces blood phenylalanine (Phe) levels in people with PKU.
If you qualify, you may receive:
– Investigational medication at no cost
– Payment for study visits
– Payment for travel costs
– Study-related monitoring
Find out if you qualify for Synpheny-3
Synpheny-3 is for adults with PKU ages 18 years and older who have Phe levels ≥ 360 μmol/L (6mg/dL) despite current management.
There is no specific diet required; participants may follow their normal diet.
A Synlogic Case Manager can discuss this with you and provide additional information.
About the Synpheny-3 clinical trial
SYNB1934 has been studied in Phase 1 and 2 clinical trials in healthy volunteers and people who have PKU.
The Synpheny-3 study includes three parts, described below.
Participants will receive increasing doses of the investigational drug to find the best dose.
Half of study participants will stay on the investigational drug. Half will receive a placebo.
Open Label Extension (OLE)
Up to 36 months
Participants will stay on the investigational drug for up to 3 years.
Before taking part in the clinical trial, you need to:
- Answer a few short questions online.
- Speak to a Case Manager. The Synlogic Case Manager will contact you within 1 to 2 business days with more information and to answer your questions.
- Speak to a clinical trial site. The Case Manager will introduce you to a clinical trial team. Members of this team will stay in close contact with you during the clinical trial.
Synlogic’s Case Manager
Leyla will contact you to discuss the Synpheny-3 clinical trial and answer your questions.
There are different ways people can participate in this study: in-person, virtually, or a combination of the two. Leyla can help you decide which format is best for you and connect you with the clinical team at that site.
Planned Clinical Trial Locations
The Synpheny-3 clinical trial will soon have a virtual site and study locations in medical centers near you.
A Synlogic Case Manager will help you decide which works best for you.
About Investigational Medication SYNB1934
SYNB1934 is a specially engineered probiotic, or healthy bacterium, that has been designed to consume Phe in the GI tract.
SYNB1934 is based on the helpful probiotic E. coli Nissle (EcN). Many people around the world use EcN as a treatment for common intestinal problems like diarrhea and constipation.